{"product_id":"adpt-bcg-matrix","title":"(ADPT) Adaptive Biotechnologies Corporation BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSee the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Adaptive Biotechnologies Corporation BCG Matrix is a strategic tool for understanding how the company’s products or business units may fit into Stars, Cash Cows, Question Marks, and Dogs. The page already shows a real preview of the actual analysis, so you can review the format and content before purchase. Buy the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eclonoSEQ multiple myeloma\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eclonoSEQ is Adaptive Biotechnologies Corporation’s flagship clinical assay for measurable residual disease monitoring in multiple myeloma, a setting where MRD has become a key depth-of-response tool. The hematologic oncology MRD market is still widening as clinicians track remission more closely, and that keeps clonoSEQ in a high-relevance, high-growth lane. Strong clinical adoption makes it a clear Star in the BCG matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eclonoSEQ B-cell acute lymphoblastic leukemia\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eclonoSEQ B-cell acute lymphoblastic leukemia is a Star because it is one of Adaptive Biotechnologies Corporation’s approved hematologic uses, with FDA-cleared MRD testing in adult and pediatric ALL. It can detect disease down to 1 cell in 1,000,000, which fits the rising need for deeper leukemia monitoring. The product is commercially scaled and linked to routine clinical decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eclonoSEQ chronic lymphocytic leukemia\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eclonoSEQ in chronic lymphocytic leukemia is Adaptive Biotechnologies Corporation’s second major hematology MRD use, after multiple myeloma. CLL is the most common adult leukemia in the U.S., with about 21,250 new cases expected in 2025, so the addressable pool is large. Repeated MRD checks can recur across treatment cycles, which supports recurring test demand. The niche also has strong clinical utility in precision oncology.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eclonoSEQ hematologic MRD platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eclonoSEQ is Adaptive Biotechnologies Corporation's core hematologic MRD platform, used for detection and longitudinal monitoring across blood cancers. Its first-mover position in NGS-based immune sequencing diagnostics supports premium positioning, and the MRD market keeps expanding as clinicians use deeper response tracking to guide treatment.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMRD supports treatment decisions.\u003c\/li\u003e\n\u003cli\u003eFirst mover in NGS diagnostics.\u003c\/li\u003e\n\u003cli\u003eBroader franchise lifts repeat use.\u003c\/li\u003e\n\u003cli\u003eGrowth plus leadership = Star.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eimmunoSEQ translational research platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eimmunoSEQ fits \"Star\" traits in Adaptive Biotechnologies Corporation's BCG mix: it supports translational research, biomarker discovery, and drug discovery, and the addressable market keeps widening as immune profiling gets more data driven in 2025-2026.\u003c\/p\u003e\n\u003cp\u003eIts value comes from broad research use and repeatable sequencing demand, but scaling still depends on converting platform traffic into durable revenue growth.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eResearch and biomarker tool\u003c\/li\u003e\n\u003cli\u003eUsed across multiple workflows\u003c\/li\u003e\n\u003cli\u003eMarket still expanding in 2025-2026\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdaptive Biotechnologies’ Star Assets Power MRD and Immune Profiling Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAdaptive Biotechnologies Corporation’s Stars are clonoSEQ in multiple myeloma, ALL, and CLL, plus immunoSEQ in research. These units sit in fast-growing MRD and immune-profiling niches, with clonoSEQ already commercially scaled and immunoSEQ still expanding across 2025-2026 workflows. That mix of growth and leadership fits Star status.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003e2025-2026 signal\u003c\/th\u003e\n\u003cth\u003eStar cue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eclonoSEQ\u003c\/td\u003e\n\u003ctd\u003eMRD to 1 in 1,000,000\u003c\/td\u003e\n\u003ctd\u003eHigh growth, high share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCLL\u003c\/td\u003e\n\u003ctd\u003e21,250 U.S. cases in 2025\u003c\/td\u003e\n\u003ctd\u003eRecurring demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eimmunoSEQ\u003c\/td\u003e\n\u003ctd\u003eBroader research use\u003c\/td\u003e\n\u003ctd\u003eExpanding platform\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eAdaptive Biotechnologies’ BCG Matrix shows where to invest, hold, or divest across Stars, Cash Cows, Question Marks, and Dogs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eQuick BCG snapshot of Adaptive Biotechnologies to spot cash cows, stars, and underperformers fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise source trail to verify Adaptive Biotechnologies assumptions, boosting credibility and speeding investor due diligence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eimmunoSEQ research services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eimmunoSEQ research services are a repeatable, research-use line with entrenched customers in academia and pharma, so demand is steadier than newer products and not tied to one clinical launch. Adaptive Biotechnologies reported 2024 revenue of about $173 million, and this service can help support cash flow with lower incremental sales spend.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiomarker discovery contracts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAdaptive Biotechnologies Corporation uses immunoSEQ data for biomarker discovery and immune profiling, and these contracts are usually recurring with pharma and biotech partners. This makes the service line more mature than pipeline bets, so it can help fund growth. In 2024, Adaptive reported about $177 million in revenue, and this cash-generating work helps offset weak spots in newer assets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical laboratory workflow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe clinical laboratory workflow is a cash cow because Adaptive Biotechnologies already runs a commercial lab for sample processing, sequencing, and reporting. In 2024, revenue was about $176 million, and scale helped gross margin improve. Once fixed lab costs are covered, each extra sample can add profit, so this is a mature base, not a high-risk growth bet.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEstablished academic customer base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAdaptive Biotechnologies Corporation’s academic and translational research base keeps immune sequencing demand steady, because studies often expand from dozens to hundreds of samples and need follow-on orders. In FY2025, this slower-growth segment still matters because repeat use is tied to active research programs, not one-time purchases. That makes it a classic Cash Cow: stable, recurring revenue with limited growth.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRepeat orders follow ongoing studies.\u003c\/li\u003e\n\u003cli\u003eDataset growth supports reorders.\u003c\/li\u003e\n\u003cli\u003eStable, low-growth revenue base.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRepeat MRD monitoring orders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRepeat MRD monitoring orders are a cash cow for Adaptive Biotechnologies Corporation because hematologic oncology patients often need serial clonoSEQ tests across treatment and follow-up. Once a center adopts the assay, the same patient can drive recurring orders, so revenue is steadier than in early-stage programs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSerial testing supports repeat orders.\u003c\/li\u003e\n\u003cli\u003eAdoption raises account-level stickiness.\u003c\/li\u003e\n\u003cli\u003eRecurring use makes cash flow more mature.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdaptive’s Cash Cow: Sticky ImmunoSEQ and clonoSEQ Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAdaptive Biotechnologies Corporation’s cash cows are immunoSEQ research services and serial clonoSEQ monitoring: both are repeat-use, low-growth lines with sticky accounts. FY2024 revenue was about $176 million, and recurring lab volume helps spread fixed costs, so these lines can keep cash flowing while newer bets scale.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCash cow\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003cth\u003eLatest revenue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003eimmunoSEQ and clonoSEQ\u003c\/td\u003e\n\u003ctd\u003eRepeat orders, steady demand\u003c\/td\u003e\n\u003ctd\u003eAbout $176 million FY2024\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eAdaptive Biotechnologies Corporation Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe Adaptive Biotechnologies Corporation BCG Matrix preview you see is the exact same document you’ll receive after purchase. There are no demo pages or hidden edits—just the full, ready-to-use report. Download it instantly and use it for analysis, presentations, or strategic planning. What you preview is what you get.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eT-Detect COVID\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eT-Detect COVID fits the Dogs bucket: it was built to confirm past COVID-19 infection, but demand fell fast after the 2020-2022 peak and the market became far less attractive. By end-2025, it looks like a low-growth, low-share asset with little pricing power and no clear path to scale. Adaptive Biotechnologies Corporation has shifted attention to higher-value immune diagnostics, while COVID serology demand has normalized sharply from pandemic levels.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eimmunoSEQ T-MAP COVID\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eimmunoSEQ T-MAP COVID was a pandemic-only assay for measuring T-cell responses to COVID-19 vaccines, so its market was tied to 2020-2022 demand. By 2025, COVID testing had normalized, and the product no longer had strong strategic pull inside Adaptive Biotechnologies Corporation’s portfolio. In BCG terms, it fits a Dog: low growth, weak long-term fit, and limited capital priority.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCOVID infection confirmation testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAdaptive Biotechnologies Corporation's COVID infection confirmation testing fits Dog territory because it rode a one-time 2020-2022 surge that has since normalized. With the WHO ending the global COVID-19 public health emergency on May 5, 2023, demand shifted to a much smaller endemic testing base, so long-term growth is weak. That makes this offer low-growth, low-share, and a poor capital allocator.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCOVID vaccine-response services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAdaptive Biotechnologies Corporation's COVID vaccine-response services sit in a small, narrow niche. They were useful during the 2021-2022 public health surge, but by fiscal 2025 they no longer look like a core growth engine.\u003c\/p\u003e\n\u003cp\u003eIn BCG terms, this is a Dog: low growth, limited scale, and weak strategic priority. One line says it all: the pandemic demand spike faded, and this service line did too.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eNiche vaccine immune-response service\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eUseful during pandemic demand peaks\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eBy 2025, not a growth driver\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eFits Dog quadrant logic\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePandemic-specific diagnostics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAdaptive Biotechnologies Corporation’s pandemic-specific diagnostics are a Dogs asset: the COVID testing market is crowded, pricing is weak, and demand has not returned to 2020-2021 peak levels. These products are unlikely to scale into a durable growth engine, so they can absorb cash without lifting long-run value. The portfolio looks like a harvest-and-contain line, not a growth driver.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow rebound odds\u003c\/li\u003e\n\u003cli\u003eHeavy competition\u003c\/li\u003e\n\u003cli\u003eCash trap risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdaptive Biotechnologies’ COVID Assays: From Pandemic Surge to BCG Dogs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAdaptive Biotechnologies Corporation’s Dogs are its pandemic-era COVID assays: demand faded after the 2020-2022 spike, and the WHO ended the global emergency on 2023-05-05. By fiscal 2025, these offers had low growth, weak pricing power, and no clear scale path. In BCG terms, they are cash-drain, low-priority assets.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eOffer\u003c\/th\u003e\n\u003cth\u003e2025 view\u003c\/th\u003e\n\u003cth\u003eBCG\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003eT-Detect COVID\u003c\/td\u003e\n\u003ctd\u003eEndemic demand, weak growth\u003c\/td\u003e\n\u003ctd\u003eDog\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMicrosoft multi-disease blood test\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAdaptive Biotechnologies Corporation’s Microsoft-linked multi-disease blood test is a Question Mark: it targets early detection from one blood sample, but commercial share is still unproven. The opportunity is large, with the global in vitro diagnostics market expected to reach about $115 billion by 2027, yet Adaptive Biotechnologies Corporation still posted only $179 million in 2024 revenue and a net loss, showing scale is not locked in. If adoption rises, this could move fast from R\u0026amp;D optionality to a growth engine.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGenentech neoantigen T-cell therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAdaptive Biotechnologies Corporation’s Genentech neoantigen T-cell therapy program is a joint effort to build cancer treatments that target patient-specific tumor mutations, but it is still in development, not revenue-generating. The broader cell therapy market was valued at about $5 billion in 2024 and is projected to grow at a double-digit CAGR through 2030, so the upside is real. Still, the program needs heavy capital, clinical proof, and manufacturing scale to move from Question Mark to Star.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAutoimmune diagnostics pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAdaptive Biotechnologies Corporation’s autoimmune diagnostics pipeline targets a huge, medically important market: autoimmune disease affects about 50 million Americans and includes more than 80 conditions. The opportunity is real, but Adaptive has not yet built dominant share in this space, so the franchise still fits a Question Mark in the BCG Matrix.\u003c\/p\u003e\n\u003cp\u003eIts immune-sequencing platform can support earlier diagnosis and monitoring, but commercial scale is still limited versus the size of the unmet need. Until Adaptive proves repeatable revenue growth and stronger adoption, this pipeline remains high-upside but unproven.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eInfectious disease pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAdaptive Biotechnologies Corporation’s infectious disease pipeline is a real upside case, because the global diagnostics market is large and recurring. But beyond COVID, its commercial traction is still not proven, so the BCG Matrix fits it closer to a Question Mark than a Star. The upside is there, but so is the risk that new assays do not scale fast enough.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLarge market, weak proof\u003c\/li\u003e\n\u003cli\u003eBeyond-COVID demand is real\u003c\/li\u003e\n\u003cli\u003eExecution risk stays high\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNon-hematologic oncology expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAdaptive Biotechnologies Corporation’s Question Mark is non-hematologic oncology: its revenue engine is still blood cancers, while solid-tumor testing and monitoring remain early-stage. The upside is real because broader minimal residual disease and cancer-detection use cases can grow fast, but share outside hematologic oncology is still small. In other words, the market is bigger than its current footprint.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCore revenue: hematologic oncology\u003c\/li\u003e\n\u003cli\u003eSolid tumors: high-growth option\u003c\/li\u003e\n\u003cli\u003eCurrent share: still low\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdaptive Biotechnologies: Big Upside, Unproven Share\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAdaptive Biotechnologies Corporation’s Question Marks have big upside but weak proof: Microsoft-linked early detection, Genentech neoantigen therapy, and autoimmune and infectious disease tests are still not dominant. In FY2024, revenue was $179 million and the company still posted a net loss, so scale is not locked in. The bet is clear: strong markets, but share is still unproven.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eArea\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2024 revenue\u003c\/td\u003e\n\u003ctd\u003e$179 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStatus\u003c\/td\u003e\n\u003ctd\u003eHigh-upside, low-share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRisk\u003c\/td\u003e\n\u003ctd\u003eClinical and adoption execution\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57233959452937,"sku":"adpt-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/adpt-bcg-matrix.webp?v=1785709479","url":"https:\/\/dcfanalyst.com\/products\/adpt-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}